Work

Kaplan-Meier analysis of the survival for patients with ATL who responded to alemtuzumab therapy from Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma

Year: 2023
Type: other
Abstract: Kaplan-Meier analysis of the survival for patients with ATL who responded to alemtuzumab therapy
Language: English
Subfield: Immunology
Open Access status: gold
OpenAlex ID: W4361929634
Cites:
Cited by:
Related to: 10